Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Other solid neoplasm 1Breast 1

Conditions

Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Solid Tumors 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Sunitinib 86Sorafenib 60Everolimus 47pazopanib 46Bevacizumab 46Nivolumab 44pembrolizumab 37aldesleukin 29Interferon-alpha 26Axitinib 24temsirolimus 23cabozantinib 20Interleukin-2 19Ipilimumab 16Interferon alpha-2 15Cyclophosphamide 15fludarabine phosphate 14Gemcitabine 14Peripheral Blood Stem Cell Transplantation 11Sirolimus 10Paclitaxel 10Erlotinib Hydrochloride 10avelumab 8Radiosurgery 8Docetaxel 8Cyclosporine 8Capecitabine 8tremelimumab 7lenvatinib 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Carcinoma, Renal Cell × CB-839 × Clear all
NCT03428217 2023-03-20

CANTATA

Calithera Biosciences, Inc

Phase 2 Completed
444 enrolled 15 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03163667 2022-09-15

ENTRATA

Calithera Biosciences, Inc

Phase 2 Completed
69 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡